RxDoctor Payments Data

Priya Swamy, MD

Physical Medicine & Rehabilitation · Broomall, PANPI 1245285741

Payments from drug & device makers

$1,995in general payments, 2019–2025

Across 112 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$762
  • Curonix LLC$455
  • Biodelivery Sciences International, Inc.$114
  • Nevro Corp.$102
  • Protega Pharmaceutials Inc$89
  • Abbott$89
  • plus $384 from 14 others

What the payments were for

  • Travel & lodging$28914%
  • Food & beverage$1,70686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,995 in reported general payments places this provider in the 85th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,727
Medicare patients
130
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl253$197,781
Xtampza ErOxycodone Myristate86$64,754
BelbucaBuprenorphine Hcl53$33,642
Oxycodone Hcl1,599$31,779
Nucynta ErTapentadol Hcl32$30,931
Buprenorphine68$18,644
LinzessLinaclotide25$12,701
Morphine Sulfate ErMorphine Sulfate346$11,110
NucyntaTapentadol Hcl13$9,988
Oxymorphone Hcl ErOxymorphone Hcl13$8,903
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen384$7,673
Fentanyl68$6,509
SymproicNaldemedine Tosylate12$5,463
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$3,718
Gabapentin330$3,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta$762$139,315184 claims
AbbVieLinzess$11$12,70125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

Other physical medicine & rehabilitation in Broomall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →